Glaxo Sues To Protect Zofran Patent
On August 9, Glaxo received notice that Eon, which recently merged with Sandoz Laboratories, had filed an Abbreviated New Drug Application seeking permission to produce a generic version of the drug.
In the complaint, Glaxo contends that Eon’s ANDA violates a patent it holds for “process and composition using ondansetron,” the active ingredient in Zofran. Glaxo was awarded...
To view the full article, register now.